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Abstract
While considerable evidence supports the causal relationship between increases in c-Myc (Myc) and cardiomyopathy as a
part of a ‘‘fetal re-expression’’ pattern, the functional role of Myc in mechanisms of cardiomyopathy remains unclear. To
address this, we developed a bitransgenic mouse that inducibly expresses Myc under the control of the cardiomyocyte-
specific MHC promoter. In adult mice the induction of Myc expression in cardiomyocytes in the heart led to the
development of severe hypertrophic cardiomyopathy followed by ventricular dysfunction and ultimately death from
congestive heart failure. Mechanistically, following Myc activation, cell cycle markers and other indices of DNA replication
were significantly increased suggesting that cell cycle-related events might be a primary mechanism of cardiac dysfunction.
Furthermore, pathological alterations at the cellular level included alterations in mitochondrial function with dysregulation
of mitochondrial biogenesis and defects in electron transport chain complexes I and III. These data are consistent with the
known role of Myc in several different pathways including cell cycle activation, mitochondrial proliferation, and apoptosis,
and indicate that Myc activation in cardiomyocytes is an important regulator of downstream pathological sequelae.
Moreover, our findings indicate that the induction of Myc in cardiomyocytes is sufficient to cause cardiomyopathy and heart
failure, and that sustained induction of Myc, leading to cell cycle re-entry in adult cardiomyocytes, represents a maladaptive
response for the mature heart.
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Introduction
c-Myc (Myc) is highly expressed in fetal, proliferating cardiac
myocytes. However, soon after birth, myocytes cease to divide
corresponding with the downregulation of Myc [1]. Interestingly,
while Myc is expressed at very low levels in the adult myocardium
under normal physiological conditions, it is upregulated rapidly in
response tovirtuallyall hypertrophicstimuliand leadstohypertrophy
rather than hyperplasia [2,3]. Myc encodes a transcription factor
that, as part of a heterodimeric complex with MAX, regulates the
expression of a multitude of genes involved in regulating cellular
proliferation and growth [4–7]. Consequently,overexpression of Myc
is commonly associated with the activation of cell cycle machinery
and tumorigenesis. Myc exerts its neoplastic function by inducing
autonomous cellular proliferation and cellular growth, blocking
differentiation, and inducing genomic instability [5–10].
In various animal models of cardiomyopathy, the upregulation of
Myc is a consistent and early change. For instance, Myc mRNA is
dramatically increased several hours after the imposition of pressure
overload in animal models [1–3]. Notably, similar changes in Myc
expression have been reported under other pathological circum-
stances including myocardial infarction and hypertrophy induced
by pharmacological stimulation [11,12]. In humans, Myc mRNA is
increased in hypertrophic cardiomyopathy patients [13]. While the
ability to detect chronological changes in humans is limited because
samples are obtained postmortem or at biopsy, the consistent
detection of Myc expression raises the question of whether the early
expression of Myc is necessary or sufficient to induce disease.
Moreover, if Myc expression is sufficient to cause disease, it is
unclear which Myc-related downstream mechanisms, such as cell
cycle re-entry, contribute to cardiomyopathy. In this regard, given
thatmitochondrialalterationsaredirectlylinkedtothedevelopment
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7172of cardiomyopathy and heart failure [14–17], it is interesting to note
that Myc also plays a role in the maintenance of mitochondrial
function [18]. While the mechanism of Myc-regulated mitochon-
drial function is unclear, the regulation of PGC-1a (PPARc
coactivator-1a) appears to be a key factor in this process since
Myc induced the biogenesis of mitochondria through a PGC-1a-
related pathway [18]. PGC-1a is a major regulatory molecule of
mitochondrial proliferation and induces synthesis of both mito-
chondrial DNA-encoded and nuclear-encoded mitochondrial
peptides. Importantly, the expression of PGC-1a is directly
associated with the development of cardiomyopathy [19,20]. Thus,
Myc may induce hypertrophic cardiomyopathy though reactivation
of the cell cycle machinery and by negatively affecting mitochon-
drial function. To test this hypothesis, using a newly developed
inducible transgenic mouse model, we examined the effect of Myc
on the development of cardiomyopathy and heart failure and
mechanisticallyevaluated alterations incell cycleand mitochondria.
Results
Establishment of MHC-Myc mice
Traditional transgenic mouse models have significant limitations
for studying the pathogenic mechanism(s) of cardiomyopathy due to
adverse effects of the transgene in development and also limitations in
studying the temporal effect of a given transgene in mice that
constitutively overexpress the transgene. To circumvent both of these
problems and to study the importance of Myc-driven cell cycle re-
entry in the pathogenesis of cardiomyopathy, we used a tetracycline-
controlled system to generate bitransgenic mice (MHC-Myc) that
inducibly overexpress Myc under the control of the aMHC gene
promoter that drives high transgene expression specifically in
cardiomyocytes [21]. To generate MHC-Myc mice, we mated the
transgenic line tet-o-Myc, which contains the tetracycline response
element adjacent to Myc cDNA [9], with the transgenic line aMHC-
rtTA (JAM8585), which drives the expression of rtTA in cardiomy-
ocytes. rtTA requires doxycycline to bind tetO and, therefore, the
transcription of Myc is activated by doxycycline (Figure 1A). The
MHC-Myc mice are derived from heterozygote crosses and, as a
result, 75% of the litter is, as expected, composed of non-bitransgenic
mice that serve as controls (+/2 doxycycline). We have not
experienced any issues in the breeding of, nor maintenance, of these
m i c ew h i c hr e m a i nh e a l t h yu n l e s st h et r a n s g e n ei sa c t i v a t e d .
To examine the inducible expression of Myc, doxycycline
(200 mg/kg) containing diet was provided for 1 week and hearts
were collected for the measurement of Myc expression. Mice
possessing both transgenes and on doxycycline diet exhibited
increased expression of Myc mRNA (Figure 1B) and protein
(Figure 1C) compared with the basal level of Myc expression in
similar animals that were not fed doxycycline. After 1 week of
induction by doxycycline, prominent expression of Myc in the
nuclei of cardiomyocytes was detected using an anti-Myc specific
rabbit monoclonal antibody. These data clearly demonstrate that
Myc expression can be tightly regulated by the doxycycline diet and
that there is little/no significant leakiness of Myc expression in the
MHC-Myc mice.
Hypertrophy and heart failure by Myc induction
Weused3–4montholdMHC-Mycmicetodeterminetheeffectof
Myc on adult cardiomyocytes. At baseline, hearts from MHC-Myc
mice were indistinguishable in terms of size, histology or echocar-
diographyfromlittermatecontrolmice.However,the overexpression
of Myc, with doxycline-diet in Myc-ON mice, resulted in 100%
mortality in 3 weeks (Figure 2C) wherease no mortality was observed
in Myc-OFF nor littermate control mice up to 14 months old, which
are the oldest MHC-Myc mice in our current colony.
To characterize the phenotype in the adult Myc-ON mice,
cardiac structure and function were assessed by echocardiography
after 2 weeks of doxycycline administration (female, 3–4 month
Figure 1. The regulation of Myc in MHC-Myc mice. (A) The rtTA molecule is driven by MHC promoter. rtTA requires doxycycline (Dox) for
binding to tetO sequence to drive expression of Myc. Without Dox, rtTA remains inactive and Myc expression is not initiated. (B) mRNA level of Myc is
measured by RT-PCR after 1 week doxycycline diet. In comparison to the basal level (Myc-OFF). (C) The level of protein expression is analyzed by
human Myc specific rabbit monoclonal antibody. The expression of Myc is strongly induced in nuclei of cardiomyocytes by doxycycline diet after 1
week (ON) but no expression of Myc is detected in control mice (OFF).
doi:10.1371/journal.pone.0007172.g001
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rally-defined overexpression of Myc resulted in a marked increase
in LV mass with concentric geometry (increased relative wall
thickness), reduced LV fractional shortening, decreased cardiac
output, increased myocardial performance index (indicating
impaired contraction and relaxation), and left atrial enlargement,
suggesting an increase in left atrial pressure (Table 1). Thus, Myc
overexpression for 2 weeks produced decompensated hypertrophic
cardiomyopathy characterized by impaired systolic and diastolic
function. Importantly, single transgenic control mice, which only
have either the Myc or the MHC-rtTA gene, on a similar
doxycycline diet showed no significant changes in any of the
parameters measured.
Consistent with the echocardiographic data, a two week
induction of Myc resulted in an approximately 2-fold increase in
gravimetric cardiac mass normalized to body weight compared
with Myc-OFF mice (Figure 2A,B). Histological analysis revealed
typical hypertrophic changes including myocardial disarray,
nuclear atypia and marked increase in fiber width (Figure 3A–C)
as well as interstitial deposition of collagen (Figure 3D). One of the
most conserved features of cardiac hypertrophy is the re-activation
of genes that are normally limited in their expression to the
embryonic stage of heart development and these are often used as
molecular markers for cardiac hypertrophy. Therefore, we
examined hypertrophic changes at the molecular level by
measuring two well known marker genes, atrial natriuretic peptide
and brain natriuretic peptide. As shown in Figure 4, the expression
of both atrial and brain natriuretic peptides was significantly
increased after 1 week induction and then decreased after 2 weeks
induction. This suggests that hypertrophic changes at the
molecular level begin early in the time course of Myc expression
and that these changes are temporarily regulated.
Cell cycle re-entry in Myc-ON mice
To test whether Myc expression induces cell cycle re-entry in
adult cardiomyocytes, we measured the expression level of PCNA,
Ki67, and cyclin D1, which increase during the cell cycle. We found
that the expression of PCNA, Ki67, and cyclin D1 was strongly and
specifically induced in cardiomyocytes in Myc-ON animals
(Figure 5). In quantification analysis, we found that 3862.8% of
cardiomyocyte nuclei in Myc-ON animals were positive for Ki67.
To confirm such aberrant cell cycle activity, we injected BrdU
(50 mg/kg bodyweight) intraperitoneally 24 hrs before sacrificing
the mice and DNA replication was measured by BrdU incorpora-
tion. Consistent with our PCNA, Ki67, and cyclin D1 data, a
significant number of cardiomyocyte nuclei (2362.8%) from Myc-
ON mice were labeled with anti-BrdU antibody although no
significant BrdU incorporation was observed in Myc-OFF mice
(Figure 5E,F). Taken together, these data suggest that the cell cycle
machinery is activated in cardiomyocytes after Myc expression.
Apoptosis is increased in Myc-ON mice
We next examined the pathological effects of induction of Myc
on apoptosis in cardiomyocytes. By comparing TUNEL staining in
Myc-ON and Myc-OFF mice, TUNEL positive cardiomyocytes
were increased in Myc-ON mice but not in Myc-OFF mice
(Figure 6A,B). Consistent with this, the active form of caspase-3,
which is increased in apoptotic cells, was also increased in Myc-
ON mice (Figure 6C,D).
Figure 2. Increase of Myc expression in adult cardiomyocytes induces cardiomyopathy and heart failure. (A) Measured heart weights
(mg) were normalized to body weight (g). 1 week Myc-ON mice demonstrate about 80% increase of normalized cardiac mass and great than 100%
increase is observed after 2 weeks and the dramatic increase of cardiac mass is observed in isolated hearts (B). (C) Myc-ON mice exhibit increased
mortality after 2 weeks of Myc induction while no lethality was observed in Myc-OFF mice (n=12).
doi:10.1371/journal.pone.0007172.g002
Table 1. Echocardiographic Analysis of MHC-Myc mice.
Myc-OFF Myc-ON
AoR (cm) 0.1560.01 0.1460.02
Left atrial (cm) 0.2360.02 0.3460.05*
myocardial performance index 0.3660.07 0.9160.34
IVSd (cm) 0.1060.01 0.1460.02*
PWTd (cm) 0.1060.01 0.1260.02*
Cardiac output (cc) 0.2860.07 0.1360.08*
EDD (cm) 0.3860.02 0.4060.05
ESD (cm) 0.2360.03 0.2860.03*
Fractional shortening 0.5360.10 0.2860.06**
LVMI (mg/g) 6611 3 64**
Relative wall thickness 0.5360.16 0.6560.06**
*p,0.05.
**p,0.001.
All data are expressed as the mean6SD. Abbreviations: aortic root diameter
(AoR), end diastolic dimension (EDD), end systolic dimension (ESD),
interventricular septal thickness in diastole (IVSd), left ventricular mass index
(LVMI), posterior wall thickness in diastole (PWTd).
doi:10.1371/journal.pone.0007172.t001
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PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e7172Figure 3. Histological analysis of hearts. Myocardial sections from Myc-OFF (A, C) and Myc-ON (B, D) were stained with hematoxylin and eosin
(A, B). Significant myocardial disarray is observed in Myc-ON mice (B). Trichrome staining (C, D) also reveals hypertrophied cardiac myocytes in Myc-
ON mice with mild fibrosis (D). Original magnification: X 400 for A and B, X 200 for C and D. Scale bar=50 mm.
doi:10.1371/journal.pone.0007172.g003
Figure 4. The change of molecular markers for cardiac hypertrophy by over expression of Myc. Total ventricular RNA from mice with
indicated Myc induction duration was analyzed by RT-PCR with specific primers. Each gene expression level was quantified and normalized with
GAPDH expression level and expressed as a relative intensity.
doi:10.1371/journal.pone.0007172.g004
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in Myc-ON mice
To confirm and extend the histological changes, the cellular
ultrastructure of ventricular tissue from Myc-ON mice was
examined by electron microscopy. Consistent with our histological
analyses (Figure 3), Myc-ON mice showed a profound disruption
of myofibrillar structure and, interestingly, a dramatic proliferation
of mitochondria (Figure 7C,F). Since the disruption of myofibrils
broadens the space mitochondria occupy and makes the
measurement of total mitochondria in a fixed area difficult, sites
Figure 5. Expression of cell cycle markers in the cardiomyocytes from Myc-ON mice. The expression of PCNA, Ki67 and cyclin D1 is
dramatically increased in the nuclei of cardiomyocytes from Myc-ON mice (B, D, F). In Myc-OFF mice, no PCNA, Ki67 and a basal level of cyclin D1 is
observed (A, C, E). DNA replication in cardiomyocyte in Myc-ON mice is confirmed by BrdU incorporation (H) compared with Myc-OFF mice (G).
Original magnification: X 400. Scale bar=50 mm.
doi:10.1371/journal.pone.0007172.g005
Cardiomyopathy and Myc
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metric measurements. Interestingly, increases in mitochondria
number and density, but decreases in size, in Myc-ON mice are
evident compared to Myc-OFF mice (Figure 7D–G). This result
suggests that mitochondrial changes occur earlier than myofibril
disruption and other pathological changes. In this regard, it is
interesting to note that PGC-1a,a major regulatory molecule of
mitochondrial proliferation, is known to play an important role
inin hypertrophic cardiomyopathy[19,20]. To determine the
involvement of PGC-1a in Myc-ON mice, we analyzed the
expression of PGC-1a and found that the level of PGC-1a was
significantly increased in the cardiomyocytes in Myc-ON mice
compared with Myc-OFF mice (Figure 7A,B). Taken together, our
data suggest that mitochondrial alterations in cardiomyocytes are
affected by Myc expression.
Cardiac mitochondrial functional analysis in Myc mice
Based on our ultrastructural findings, and since defects in
mitochondrial metabolism contribute to the pathogenesis and
progression of heart failure, we explored whether functional
deficits in mitochondrial metabolism were associated with the
observed changes in size and number of mitochondria in Myc-ON
mice. Myc-ON expression led to a decrease in protein yield of
mitochondria compared to the Myc-OFF or single transgenic mice
(Table 2). Moreover, the specific activity of citrate synthase, a
mitochondrial marker enzyme, was decreased in the mitochondria
from Myc-ON mice compared to the mitochondria from Myc-
OFF or single transgenic mice (Myc-ON 35406160* mU/mg
protein, n=5 , p,0.05 vs. both Myc-OFF 41596144, n=5, and
Single Tg 41056156, n=4). With glutamate plus malate as the
donor of reducing equivalents to complex I, the rate of state 3
respiration was lower in Myc-ON compared to the Myc-OFF or
single transgenic mice and state 4 respiration was also decreased in
Myc-ON mitochondria compared to other groups. In contrast, the
respiratory control ratio (RCR, state3/state4) was higher in Myc-
ON mouse mitochondria compared to the Myc-OFF or single
groups and there was no difference in the ADP/O ratio among
groups (Table 2). With succinate plus rotenone as the complex II
substrate, respiration was also decreased in Myc-ON mitochon-
dria. The decreased oxidation in the presence of dinitrophenol
localizes the defect to the mitochondrial electron transport chain
(Table 2, Figure 8).
Decreases in glutamate or succinate oxidation can be due to
defects at complex III or complex IV (cytochrome oxidase). In this
regard, TMPD-ascorbate donates electrons to cytochrome oxidase
via cytochrome c and, importantly, unchanged TMPD oxidation
excludes a defect at complex IV and further implicates upstream
complexes (Figure 8). To further localize the defective sites within
the electron transport chain, we directly measured the activities of
complex I, complex II, and complex III and, consistent with above
data, the conditional expression of Myc (Myc-ON) led to
decreased activities of complex I and NCR compared to the
Myc-OFF or single transgenic mice (Figure 8). NCR measures
complex I–III activity with complex I considered to be the rate
controlling step and, as such, the decreased rate of NCR supports
a complex I defect in the electron transport chain in Myc-ON
mice. To further dissect the defect within complex I, we
determined the activity of NFR (a proximal part of complex I)
[22]. The activity of NFR was unchanged in Myc-ON mice,
indicating that the defect is distal to the first part of complex I in
Myc-ON mice.
Complex II activity was not altered by Myc-ON gene
expression (data not shown) and the decrease in succinate driven
respiration without a change in complex II activity coupled with
Figure 6. Increased apoptosis in Myc-ON mice. TUNEL positive nuclei (arrows) are specifically localized in the cardiomyocyte nuclei of Myc-ON
mice (B) but not in Myc-OFF mice (A). The active form of caspase-3 was detected by anti-cleaved caspase-3 antibody and the increase number of
positive cells is found in Myc-ON mice (D) but not in Myc-OFF mice (C). Original magnification: X 400. Scale bar=50 mm.
doi:10.1371/journal.pone.0007172.g006
Cardiomyopathy and Myc
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defect at complex III [23]. Direct measurements confirmed that
the activity of complex III was significantly (p,0.05) decreased in
Myc-ON mice (Figure 9). Complex III has three catalytic subunits:
cytochromes b, c1 and the iron-sulfur protein and, interestingly, the
decrease of cytochrome b content without affecting cytochrome c1
content was observed in Myc-ON mice and the content of
cytochrome c and aa3 were also decreased in Myc-ON mice
(Table 3). Since each complex III monomer contains a single
cytochrome b subunit, we calculated the complex III turnover
number using the ratio of complex III activity/cytochrome b
content. The decreased complex III turnover in Myc-ON mice
mitochondria suggests that the decrease in respiration through
complex III in Myc-ON mice was due to a decreased content of
complex III in mitochondria as well as a decreased activity of
complex III per each monomer.
Discussion
In this study, to study the pathological role of Myc in
cardiomyopathy and heart failure, we developed and character-
ized a newly established bi-transgenic mouse (MHC-Myc), which
expresses Myc specifically in cardiomyocytes in a doxycycline-
dependent manner. Since Myc is only expressed temporally during
development, not in adult, in cardiomyocytes, the ability to
regulate the expression of Myc after development was especially
important in this study. In MHC-Myc mice, the expression of Myc
is tightly regulated by doxycycline and no significant phenotype is
observed until Myc was induced. However, induction of Myc
(Myc-ON) for two weeks led to dramatic changes in the heart
including an ectopic reactivation and expression of cell cycle
markers in cardiomyocytes and mitochondrial perturbations that
culminated in severe hypertrophy and, ultimately, death. These
results strongly support the notion that increased Myc in adult
Figure 7. The expression of PGC-1a and mitochondrial alteration in Myc-ON mice. The expression of PGC-1a is examined by PGC-1a
specific antibodies. The representative figures demonstrate strong induction of PGC-1a in the cardiomyocytes of Myc-ON mice (B) compared with
Myc-OFF mice (A). Low-power electron microscopy reveals displacement of myofibrils in Myc-ON mice (C). The number and density of mitochondria
are increased in Myc-ON mice (D) compared with Myc-OFF mice (E). Morphometric analysis demonstrated about 2.5 fold increase of mitochondria
number and about 30% decrease of mitochondrial size in the cardiomyocytes of Myc-ON mice (p,0.05) compared with Myc-OFF mice (F). n: nucleus,
m: myofibrils, mito: mitochondria. Original magnification: X 400 for A and B, X 30,000 for C, D and E.
doi:10.1371/journal.pone.0007172.g007
Table 2. The rate of oxidative phosphorylation (nAO/min/
mg) in isolated mitochondria with glutamate and malate as
complex I substrates.
Single Tg (n=4) Myc-OFF (n=5) Myc-ON (n=5)
Protein yield (mg/g) 17.660.3 18.961.6 16.561.0*
State 3 (0.2 mM ADP) 320612 323620 259621*
State 3 (2 mM ADP) 301619 321621 209631*
Dinitropenol (0.2 mM) 293619 300615 206638*
State 4 (ADP limited) 74626 9 625 0 69*
RCR (state3/state4) 4.460.2 4.760.3 6.361.7*
ADP/O 2.9760.06 3.0360.07 3.1260.07
Mean6SEM.
*p,0.05 vs. Myc-OFF and Single Tg mice. RCR, respiratory control ratio; DNP,
2 mM ADP was used to measure state 3 respiration under conditions of
saturating ADP.
doi:10.1371/journal.pone.0007172.t002
Cardiomyopathy and Myc
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myopathy and is consistent with a previous report showing that the
conditional inactivation of Myc attenuates cardiac hypertrophy
induced by pressure overload and other hypertrophic stimuli [24].
However, in contrast to a previous Myc inducible mouse model
[25], induction of Myc in MHC-Myc animals ultimately causes
heart failure resulting in death in a relatively short duration (2–3
weeks). This difference is likely a consequence of mouse strain and
expression level of Myc (Robb MacLellan, personal communica-
tion). While our MHC-Myc mouse is derived from FVB strain, the
transgenic mouse line used by others [25,26] is derived from
C57Bl/6 and C3H mixed background. Since the effect of genetic
background on the development of cardiomyopathy and heart
failure is well documented [27,28], it is likely that genetic factor(s)
affect subsequent phenotypes. In addition, our MHC-Myc mouse
studies here appear to have significantly higher levels of Myc
expression and, consequently, a more robust phenotype than
previous models. Supporting this, the number of cardiomyocytes
re-entering the cell cycle in our MHC-Myc animals is much
greater than reported previously [24,25]. Therefore, the different
phenotypes observed between transgenic mice is likely a
consequence of the extent to which cardiomyocytes re-enter the
cell cycle and progress into S phase, leading to the development of
hypertrophy and consequent heart failure. Supporting this, recent
studies have suggested that the adult myocardium is capable of
limited cell division in certain pathological conditions [29,30]. For
instance, heart regions adjacent to a myocardial infarction show a
significant increase of Ki-67 proliferation index, while no changes
were noted distant from the lesion. Additionally, mitotic activity in
cardiomyocytes is increased nearly 10-fold increase in end-stage
ischemic heart disease and in idiopathic dilated cardiomyopathy
[29]. Therefore, our data, in addition to other studies, strongly
suggests that the reactivation of cell cycle in adult cardiomyocytes
plays an important role in the development of cardiomyopathy
and heart failure. This said, further study into the relationship to
cell cycle re-entry as an adaptive or maladaptive process is clearly
necessary.
Another important finding of our study is that Myc induces the
morphological and functional alterations of mitochondria in
MHC-Myc mice. Since PGC-1a related pathways can be directly
regulated by Myc [18], we suspect that Myc-mediated PGC-1a
regulation, which is tightly related with mitochondrial biogenesis
and function, is a key pathway for the development of
hypertrophic cardiomyopathy and heart failure in MHC-Myc
Figure 8. The expression of Myc leads to a decreased rate of dinitrophenol uncoupled respiration when glutamate+malate and
succinate+rotenone were used as complex I and complex II substrates compared to the mitochondria from Myc-OFF or single
transgenic mice (Single Tg) (Panel A). Myc did not affect the oxidation of TMPD-ascorbate (Panel A). Direct measurement of electron transport
chain enzyme activity shows that Myc decreased activities of complex I, NCR (NADH cytochrome c oxidoreductase), and complex III (Panel B). Data are
expressed as mean6SEM; * p,0.05 vs. Myc-OFF and Single Tg. n=5 for Myc-ON and Myc-OFF, and n=4 for Single Tg.
doi:10.1371/journal.pone.0007172.g008
Cardiomyopathy and Myc
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PGC-1a, driven by the a-myosin heavy chain promoter, leads to
marked mitochondrial proliferation, severe cardiomyopathy and
death [19]. Further, of more physiologic relevance, is a model of
inducible PGC-1a overexpression in the adult mouse, which leads
to a more subtle increase in mitochondrial number and the
development of a reversible cardiomyopathy, with both systolic
and diastolic functional impairment [20]. The potential mecha-
nism(s) of mitochondrial-mediated cardiac dysfunction by PGC-1a
overexpression likely involves defects in mitochondrial oxidative
metabolism or the increased production of reactive oxygen species
[20]. Consistent with this notion, the increase of PGC-1a in our
MHC-Myc mice was concomitant with an increase in mitochon-
drial number, a decrease in mitochondria size, and a reduction in
the activity of mitochondrial oxidative metabolism. While the
mechanistic basis for PGC-1a-mediated cardiomyopathy is
unclear, it is likely that dysregulated mitochondrial metabolism
and/or morphological alteration play an important role in the
development of cardiomyopathy and heart failure. Interestingly, a
recent study demonstrated an increased level of PGC-1a, but not
activity, in failing human hearts suggesting that, despite the
increase of PGC-1a, downstream pathways were disturbed by
other mechanisms to induce mitochondrial pathologies [31]. Our
observations in MHC-MYC mouse are consistent with these data
from human patients as we also observed an increase of level of
PGC-1a accompanied by functional deficits in mitochondrial
energy metabolism.
Notably, it is well established that defects in electron transport
chain complexes I [14], complex III [15] and IV [16] lead to
dilated cardiomyopathy in human patients. Moreover, the enzyme
activity of electron transport chain complexes is decreased in
hearts explanted from patients with end-stage heart failure [15,32–
36] and, importantly, end-stage heart failure also results in re-
expression of Myc as well as decreases in complexes I, III, and IV,
and mutations in mtDNA [33,34]. Therefore, the functional defect
in mitochondrial energy metabolism in MHC-Myc mice is likely a
key mechanism for the development of cardiac phenotypes such as
hypertrophy and heart failure. Regarding this, the smaller size of
mitochondria may also explain the defect in mitochondrial
function coupled with an increase of mitochondrial number. In
fact, our biochemical analyses show that citrate synthase, amount
and activity, is decreased in MHC-Myc mice. Since citrate
synthase is a mitochondrial matrix marker enzyme, reflecting
relative mitochondrial abundance and purity, these results suggest
that Myc may increase the number of immature mitochondria.
The decrease in cytochrome content and multiple defects in the
electron transport chain further supports the notion that
mitochondrial development may be incomplete in Myc-ON mice
[17]. Collectively, these findings could explain increased mito-
chondrial number coupled with decreased activities of citrate
synthase, complex I, and complex III.
In conclusion, our findings using a novel transgenic mouse with
cardiomyocyte-specific expression of Myc (MHC-Myc mice)
clearly demonstrate that increased expression of Myc can induce
hypertrophic cardiomyopathy and heart failure in vivo. Mechanis-
tically, dysregulation of cell cycle and concomitant mitochondrial
alteration are likely key pathogenic mechanisms for subsequent
hypertrophy-induced heart failure. As such, therapeutics targeted
toward Myc, cell cycle re-activation, and/or mitochondrial
dysfunction may provide opportunities for the treatment and
management of cardiomyopathies.
Materials and Methods
Animals
We used the reverse tetracycline transactivator (rtTA) system to
generate bi-transgenic mice that inducibly overexpress human c-
Myc cDNA under the control of a-myosin heavy chain (MHC)
promoter to drive high transgene expression specifically in the
cardiomyocyte. All MHC-Myc mice were derived from crossing
aMHC-rtTA [21] and tet-o-Myc mice [9], and the genotypes of the
F1 progeny confirmed by PCR. All mice in this study were
conceived and raised without doxycycline to prevent any potential
developmental consequences from the expression of Myc. To
induce Myc expression in cardiomyocytes, doxycycline-containing
food (200 mg/kg; Bio-Serve, Frenchtown, NJ) was provided ad
libitum to animals and sequential echocardiograms were performed.
Thereafter, animals were sacrificed for further pathophysiological
analysis. Importantly,inpreliminaryexperiments,we foundthat the
doxycycline diet had no effect on single transgenic littermates,
which were used as a single transgenic mouse control, on the
developmentofcardiachypertrophy nor otherbiochemical analyses
performed in this study. All study protocols were approved by Case
Western Reserve University School of Medicine Institutional
Animal Care and Use Committee.
Immunocytochemistry
Formalin fixed hearts were processed and embedded in paraffin.
Six mm thick serial sections were cut, mounted onto slides and
Figure 9. The complex III turnover is decreased in Myc-ON mice
(n=5) compared with the Myc-OFF (n=5) or single transgenic
mice (Single Tg) (n=4). Complex III turnover (sec
21)=complex III
activity (nmol/mg protein/sec)/cytochrome b content (nmol/mg
protein). Data are expressed as mean6SEM; { p,0.05 vs. Myc-OFF or
single transgenic mice (Single Tg).
doi:10.1371/journal.pone.0007172.g009
Table 3. Cytochrome contents (nmol/mg protein) in isolated
mouse heart mitochondria.
cc 1 ba a 3
Single Tg (n=4) 0.4960.02 0.1860.01 0.2960.01 0.7260.03
Myc-OFF (n=5) 0.4860.01 0.1960.01 0.2760.01 0.6760.03
Myc-ON (n=5) 0.3960.02* 0.1660.01 0.2260.01* 0.5260.05*
Mean6SEM.
*p,0.05 or 0.01 vs. Myc-OFF and Single Tg mice.
doi:10.1371/journal.pone.0007172.t003
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wasperformedbytheABCmethodaccordingtothe manufacturer’s
protocol (Vector Lab, Burlingame, CA). Anti-PCNA mouse
monoclonal antibody (Santa Cruz Biotech, Santa Cruz, CA), anti-
Myc rabbit monoclonal antibody (Epitomics, Burlingame, CA),
anti-Ki67 mouse monoclonal antibody (Dako, Carpinteria, CA),
anti-PGC-1arabbitpolyclonalantibody(SantaCruzBiotech,Santa
Cruz, CA) and anti-Cyclin D1 rabbit antibody (Thermo Scientific,
Waltham, MA) were used. Antibody reactivity was localized using
3-39-diaminobenzidine as a chromogen (Dako, Carpinteria, CA).
To exclude the possibility of non-specific reaction, all the
immunocytochemistry experiments contained at least one sample
without a primary antibody. Haemotoxylin and eosin staining and
Trichrome staining were also performed for routine histochemical
and morphological analyses. Quantification of Ki67- and BrdU-
positive cardiomyocytes was performed on slides stained and
counterstained with haematoxylin. Four areas of kleft venticles
were randomly selected on an Axiophot microscope (Zeiss,
Thornwood, NY) and at least 100 positive cardiomyocytes were
counted per area. Percent positive was calculated by dividing the
percent positive nuclei by total number of cardiomyocytes counted
per experimental group (n=3).
RT-PCR
mRNA was isolated from heart tissues using an RNeasy kit
(Qiagen, Valencia, CA). RT-PCR was carried out using the
RETROscript RT-PCR kit (Ambion, Austin, TX) according to the
manufacturer’s instructions. Briefly, purified total RNA (100 ng) was
reverse transcribed with cloned MMLV reverse transcriptase (50 U)
by incubating at 44uC for 60 min, followed by heating at 92uCf o r
10 min. The resulting single-stranded cDNA was then amplified
u s i n gap a i ro fp r i m e r sf o re a c ht a r g e tg e n e( 2 5p m o l )a n dT a qD N A
polymerase (2.5 U; Roche, Indianapolis, IN) for the indicated
number of cycles of amplification (30 sec at 94uC for denaturing,
30 sec at 61uC for primer annealing, and 30 sec at 72uCf o rp r i m e r
extension). The RT-PCR products were then subjected to electro-
phoresis in a 1.5% agarose gel. The nucleotide sequence used for
each primer was as follows: for c-Myc: 59-primer, 59-TCTGGAT-
CACCTTCTGCTGG-39;3 9-primer, 59-CCTCTTGACATTT-
CTCCTCGG-39, for atrial natriuretic peptide: 59-primer, 59-
CATCACCCTGGGCTTCTTCCT-39;3 9-primer, 59-TGGGC-
TCCAATCCTGTCAATC-39, for brain natriuretic peptide: 59-
GCG GCA TGG ATC TCC TGA AGG-39;3 9-primer, 59-CCC
AGG CAG AGT CAG AAA CTG-39,a n df o rG A P D H :5 9-primer,
59-ATGTTCCAGTATGACTCCACTCAGG-39;3 9-primer, 59-
GAAGACACCAGTAGACTCCACGACA-39.
TUNEL analysis
Detection of 39-OH termini of DNA strand breaks was
performed on paraffin sections using the In Situ Cell Death
Detection Kit (Roche, Indianapolis, IN) following the recommen-
dations of the manufacturer. Briefly, the tissue sections were
treated with proteinase K (20 mg/ml in 10 mM Tris-HCl, pH 7.4)
for 30 min at 37uC after rehydration. After rinsing slides with
phosphate buffered saline, TUNEL reaction mixture containing
terminal deoxynucleotidyl transferase and fluorescence labeled
nucleotide was applied for 1 hr at 37uC. Positive signals were
observed directly using fluorescence microscopy. Positive and
negative controls were run in parallel on adjacent sections to
confirm the specificity of the assay.
BrdU incorporation analysis
DNA synthesis was directly examined by analysis of 5-bromo-
29-deoxyuridine (BrdU) incorporation. For this experiment,
50 mg/kg of the thymidine analog BrdU (Sigma, St. Louis, MO)
was intraperitoneally injected into each mouse. One day after
injection, hearts were removed and embedded in paraffin,
sectioned, and mounted on slides. The sections were treated with
2N hydrochloric acid for 2 hr and then washed two times with 1x
Tris-buffered saline (3 min each) to neutralize the acid. Incorpo-
rated BrdU was detected with an anti-BrdU rat monoclonal
antibody (Abcam, Cambridge, MA) diluted 1:200 by the ABC
method as described above.
Electron microscopy
Electron microscopy on tissue sections was performed as
described previously [37,38]. Briefly, tissue was immediately fixed
in 1.5% glutaraldehyde in cacodylate buffer, pH 7.4 for 1 hour at
room temperature and postfixed in 1% osmium tetroxide for
1 hour. After dehydration in graded ethanol and propylene oxide,
the tissue was embedded in epoxy resin, then sectioned at silver
interference color. Thin sections were stained with uranyl acetate
and lead citrate, and examined in a JEOL 1200EX electron
microscope (Tokyo, Japan).
Echocardiographic analysis
Mice were weighed and anesthetized with isoflurane (induced at
3% and maintained at ,1% by nosecone). After shaving the chest,
the extremities were secured to a warming pad (Braintree
Scientific, Braintree, MA) with paper tape and needle electrodes
were connected to a preamplifier to simultaneously record a single
lead electrocardiogram. Pre-warmed, centrifuged (to eliminate air
bubbles) ultrasound transmission gel was applied to the chest and
2D-directed M-mode and Doppler echocardiographic studies were
performed using a 15 MHz (15L8) linear array transducer
(Sequoia, Siemens, Mountain View, CA). Mice were imaged in
the shallow left lateral decubitus position and short and orthogonal
long axis and apical views were obtained. The M-mode
dimensions included the end-diastolic (LV EDD) and end-systolic
(LV ESD) diameters [taken from the short axis at the level of the
largest left ventricle (LV) diameter], end-diastolic posterior
(EDPWTh) and end-diastolic septal (EDSWTh) wall thicknesses,
the LV outflow tract diameter (LVOT) and left atrial and, aortic
root dimensions. Doppler variables included the peak and velocity
time integral (vti) of aortic flow, and aortic ejection time.
Simultaneous transmitral and LV outflow velocities were obtained
for calculation of the relatively heart rate-independent myocardial
performance index (MPI), which is a measure of combined systolic
and diastolic function [39]. The MPI is the sum of the isovolumic
contraction and relaxation times divided by the aortic ejection
time. Other derived echo indices included the LV fractional
shortening (FS=(EDD-ESD)/EDD), LV mass [LVM=1.06*
(EDD+EDPWTh*EDSWTh)
3-EDD
3)], relative wall thickness
[RWT=(EDWTh+EDSWTh)/EDD)], and cardiac output
[CO=(LVOT/2)
2*aortic vti*heart rate]. LV mass was normal-
ized by the body weight. Studies were performed by a sonographer
who was blinded to genotype.
Mitochondria isolation
A single population of cardiac mitochondria, consisting of a
combination of subsarcolemmal and interfibrillar mitochondria,
was isolated using protease treatment. Cardiac tissue from a pool
of 3 to 5 mouse hearts was finely minced and placed in buffer A
[containing (in mM) 100 KCl, 50 MOPS, 1 EGTA [ethylene
glycol-bis (b-aminoethyl ether)-N,N,N9,N9-tetraacetic acid], 5
MgSO4N7H 2O, and 1 ATP; pH 7.4] at 4uC. The minced tissue
was homogenized and incubated for 30 sec at 4uC in the presence
of protease (5 mg/g wet tissue). Buffer B (Buffer A+0.2% bovine
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mixed homogenate was quickly centrifuged at 8,000 g for 10 min,
and the supernatant was discarded. The pellets were re-suspended
in buffer B, centrifuged at 500 g for 10 min, and the supernatant
saved for mitochondria isolation. The pellets were resuspended
one more time, washed in Buffer B, re-centrifuged, and the
remaining pellet discarded. The combined supernatants were
centrifuged at 3,000 g to sediment mitochondria, which were
sequentially washed with buffer B followed by KME (100 mM
KCl, 50 mM MOPS, and 0.5 mM EGTA). Mitochondria were
suspended in KME and the protein content was determined by the
biuret method using bovine serum album as a standard [23].
Mitochondrial oxidative phosphorylation and oxidase
activities
Oxygen consumption in mitochondria was measured using a
Clark-type oxygen electrode at 30uC [23]. Mitochondria were
incubated in a buffer [containing (in mM) 80 KCl, 50 MOPS, 1
EGTA, 5 KH2PO4, and 1 mg/ml BSA, at pH 7.4]. Glutama-
te+malate (complex I substrate), succinate (complex II substrate),
and TMPD (N,N,N9,N9 tetramethyl p-phenylenediamine)-ascor-
bate (complex IV substrate) were used as donors to specific sites in
the electron transport chain. Rotenone (5 uM) was used with
succinate and TMPD-ascorbate to prevent reverse electron flow.
State 3 (ADP-stimulated), state 4 (ADP-limited) respiration,
respiratory control ratio, and the ADP/O ratio were measured
[23]. Dinitrophenol (0.2 mM) was used to determine the maximal
rate of uncoupled respiration independent of the phosphorylation
apparatus including complex V.
Electron transport chain and citrate synthase enzyme
activities
The following enzyme activities were measured at 37uCi n
detergent-solubilized mitochondria using previously described
methods [40–42]: NADH-cytochrome c reductase (NCR), rote-
none-sensitive; NADH-decylubiquinone reductase, rotenone sen-
sitive (complex I); NADH ferricyanide reductase (NFR); Succi-
nate-decylubiquinone reductase (complex II); Decylubiquinol
cytochrome c oxidoreductase (complex III); and citrate synthase.
Statistics
Statistical comparisons were performed by parametric analysis
using a one-way analysis of variance (ANOVA) and/or Students’
t-test, as appropriate, to determine significant differences across
experimental groups. The null hypothesis was rejected at p,0.05.
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